In UK practice today, most people should be on something other than zidovudine. Its remaining role is narrow and the reasons to avoid it are broader than for any other drug on this site.
Who should not take it?
Anyone with low blood counts, since bone marrow suppression is its main toxicity. Anyone with a history of significant anaemia or neutropenia. Anyone with a previous hypersensitivity reaction.
What about liver disease?
Caution in significant liver impairment, with dose reduction where it is used at all. Anyone with advanced liver disease from hepatitis B or C needs this considered when a regimen is chosen.
What about kidney impairment?
Dose reduction is needed in significant impairment. Because combination tablets containing it are fixed-dose, that generally means separate components or a different regimen.
Who is excluded by other medicines?
Anyone on ganciclovir, ribavirin, stavudine, or chemotherapy agents that suppress the marrow. The ribavirin and stavudine combinations are antagonistic and the marrow combinations compound its main problem.
What about a history of muscle problems?
Worth raising. Zidovudine causes myopathy with prolonged use, and someone with an existing muscle disorder or a previous episode has a reasonable case for something else.
What about lipoatrophy?
Anyone who has already experienced fat loss on a thymidine analogue should not be given another. The changes can be irreversible, and there is no reason to risk adding to them.
What about pregnancy?
This is where it retains a genuine role. It has the longest record of any antiretroviral in pregnancy and in newborns, and is still used in some circumstances during labour and for infants after birth.
Does that mean it is preferred in pregnancy?
Not generally for treatment, where modern combinations are used. Its role is specific, mainly where the viral load is not fully suppressed at delivery, and it is decided by a specialist team.
When else is it still used?
In certain resistance patterns, since the M184V mutation increases susceptibility to it. And where other nucleoside analogues cannot be used for a specific reason. Both are specialist situations.
What if you have been on it for years?
Worth a conversation. Anyone still taking zidovudine long term should ask whether a modern alternative would suit them better, since the tolerability difference is substantial and switching while suppressed is routine.
Would switching lose anything?
Rarely. Modern nucleosides are at least as effective and considerably better tolerated. The exception is where a specific resistance pattern makes zidovudine uniquely useful, which a resistance test would show.
What are the alternatives?
Tenofovir disoproxil or tenofovir alafenamide with emtricitabine, which also cover hepatitis B. Abacavir with lamivudine, for anyone without the HLA-B*5701 gene variant. Two-drug regimens such as dolutegravir with lamivudine.
Why were they developed?
Largely in response to zidovudine's problems. The reduction in mitochondrial toxicity between it and modern nucleosides is one of the clearest improvements in the history of HIV treatment.
Is it ever the only option?
Very rarely, and where it is, a specialist will have constructed the regimen around a specific resistance profile. Being told it is your only option is worth a second opinion.
Who decides?
You do, with a clinician. If you are on zidovudine and struggling, that is sufficient reason to ask for a change, and in current UK practice the answer will usually be yes.